Patient Perception of Prolapse Condition Questionnaire: A Validated Patient-Reported Outcome Measure.

Introduction And Hypothesis: Identifying patient-reported outcome measures allows management of urogenital prolapse to be tailored to reflect symptom bother and expectations of treatment. We devised a new single-item questionnaire, the Patient Perception of Prolapse Condition (PPPC), based on the Patient Perception of Bladder Condition (PPBC). The aim was to evaluate the criterion validity, test/re-test reliability and responsiveness of the PPPC.

Anal incontinence following obstetric anal sphincter injury: Is there a difference between subtypes? A systematic review.

Aims: Obstetric anal sphincter injury (OASI) is associated with long-term anal incontinence (AI). We aimed to address the following questions: (a) are women with major OASI (grade 3c and 4) at higher risk of developing AI when compared to women with minor OASI (grade 3a and 3b)? (b) is a fourth-degree tear more likely to cause AI over a third-degree tear?

Methods: A systematic literature search from inception until September 2022. We considered prospective and retrospective cohort studies, cross-sectional and case-control studies without language restrictions.

Changing surgical trends for female stress urinary incontinence in England.

Introduction And Hypothesis: Stress urinary incontinence (SUI) surgery has significantly evolved with the introduction of synthetic midurethral slings (MUS). However, following reports from the US Food and Drug Administration and European Commission, the use of vaginal meshes in urogynaecology has been largely scrutinised. We analysed trends in female SUI surgery in England from 2000 to 2017.

Trends in prolapse surgery in England.

Introduction And Hypothesis: Women have a lifetime risk of undergoing pelvic organ prolapse (POP) surgery of 11-19%. Traditional native tissue repairs are associated with reoperation rates of approximately 11% after 20 years. Surgery with mesh augmentation was introduced to improve anatomic outcomes.

Current evidence and emerging drug therapies for overactive bladder.

Overactive bladder is a common symptom complex with health related quality of life impacts on the individual as well as utilizing health resources. Antimuscarinic therapy has been the mainstay of treatment and is well supported within the literature and guidelines. However, compliance is poor due to lack of efficacy and adverse events leading to the development of novel therapies.

Is there any association between urodynamic variables and severity of overactive bladder in women with idiopathic detrusor overactivity?

Aims: The lack of a validated detrusor overactivity (DO) severity tool limits the clinical value of urodynamics in the management of patients with overactive bladder syndrome (OAB). The aim of this study, was to identify urodynamic variables that correlate with validated OAB severity measures.

Methods: This was a cross-sectional study enrolling consecutive women with idiopathic DO.

Therapies in early development for the treatment of urinary tract inflammation.

Introduction: Urinary tract inflammation is a very common clinical condition. It is caused by several pathogens and antibiotic treatment is the mainstay of therapy. Increasing antimicrobial resistance and high recurrence rates represent a challenge.

The efficacy and tolerability of mirabegron, a β3 adrenoceptor agonist, in patients with symptoms of overactive bladder.

Mirabegron, is the only β-3 adrenoreceptor (AR) agonist available for the treatment of overactive bladder (OAB). To assess the efficacy and tolerability of this novel drug therapy, two phase II and six phase III Astellas-sponsored trials have been conducted with over 10,500 adults with OAB recruited. Of these, seven were randomized, double blind, 12-week placebo controlled studies and the other was for 12 months and not placebo controlled.

Novel targeted bladder drug-delivery systems: a review.

The objective of pharmaceutics is the development of drugs with increased efficacy and reduced side effects. Prolonged exposure of the diseased tissue to the drug is of crucial importance. Drug-delivery systems (DDSs) have been introduced to control rate, time, and place of release.

Digital assessment and quantification of pelvic organ prolapse (DPOP-Q): a randomised cross-over diagnostic agreement trial.

Introduction: Pelvic Organ Prolapse Quantification (POP-Q) system, measured in centimetres using a ruler (e.g. POPstix®), is recommended to quantify prolapse severity.

Is there a link between preoperative fluoroscopic cough stress testing and synthetic midurethral tape outcome?

Objectives: The primary aim of our study was to assess the utility of fluoroscopic cough stress testing as a predictor of synthetic midurethral tape (MUT) outcome. The secondary aim was to examine whether baseline demographics, clinical symptoms and urodynamic variables could predict MUT success.

Study Design: We carried out a retrospective study including women with stress urinary incontinence (SUI) who underwent retropubic MUT in a tertiary referral urogynaecology unit.

Management of recurrent stress urinary incontinence after failed midurethral sling: a survey of members of the International Urogynecological Association (IUGA).

Introduction And Hypothesis: Synthetic midurethral slings (MUS) have gained popularity in the management of stress urinary incontinence (SUI), due to their efficacy and minimally invasive nature. As there are no robust data to guide management of persistent or recurrent SUI after failed MUS, the aim of this study was to evaluate the management of these cases among IUGA members.

Methods: A pretested, web-based survey designed to explore assessment, surgical management and views about future research was sent to IUGA members.

Phase II drugs that target cholinergic receptors for the treatment of overactive bladder.

Introduction: Overactive bladder (OAB) is a term used to describe the symptom syndrome of urgency, with or without urgency incontinence, usually associated with frequency and nocturia. Antimuscarinics are the most widely prescribed class of drugs for OAB, although their systemic adverse effects limit their use in clinical practice as compliance. This has led to developments in the field.

Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome.

Background: Polycystic ovary syndrome (PCOS) is the most common endocrine cause of hirsutism, acne and pattern alopecia, often characterised by ovulation disorders (usually manifested as oligo- or amenorrhea). In addition, 30-40% of women with PCOS have impaired glucose tolerance, and a defect in the insulin signalling pathway seems to be implicated in the pathogenesis of insulin resistance. For this reason, insulin-lowering medications represent novel approach in women with PCOS.